Introduction {#S1}
============

In 1987, the discovery that Duchenne muscular dystrophy (DMD) is caused by the absence of the protein dystrophin in skeletal muscle fibers ([@R01]) first provided a rationale for molecular treatments, aimed at restoring dystrophin expression. Shortly thereafter, the discovery that Becker muscular dystrophy (BMD) is a milder allelic form of dystrophinopathy, in which dystrophin is present but qualitatively altered and quantitatively reduced ([@R02]) suggested that clinical benefit may be provided to DMD patients, even with partial restoration of dystrophin expression. Despite the hope stirred by these seminal discoveries, after three decades such molecular treatments are not yet widely available to DMD patients. In fact, formidable obstacles still stand in the way of the translation of dystrophin-restoring treatments from proof-of-concept experiments to clinical trials and everyday clinical practice: for instance, because of several genetic and environmental factors, there is considerable variability in disease progression , which has made the design and interpretation of clinical trials more challenging ([@R03], [@R04]). Nevertheless, several molecular therapies for DMD have reached advanced stages of clinical experimentation, and the first drugs have recently reached the market through accelerated and provisional regulatory approvals ([@R05], [@R06]).

In the complex and swiftly changing scenario of experimental treatments for DMD, the expression \"molecular therapy\" requires a more precise definition. Dystrophin restoration may be achieved in two different ways: through genetic therapies, i.e. delivery of new genetic material, that is not naturally present in the patient\'s cells, such as a functioning copy of the DMD gene or transcript; or through molecular therapies, i.e. small or larger molecules (i.e. oligonucleotides, enzymes), that interact with the patients\' own genetic material and transcription/translation machinery to restore the expression of viable dystrophin. Here, we intend to focus on molecular therapies, mainly for two reasons: first, molecular therapies have reached more advanced stages in human experimentation than genetic therapies for DMD, and are therefore of more immediate interest to neuromuscular clinicians; and second, they highlight the importance of reaching a well-defined molecular diagnosis, at the genomic level, in DMD. In fact, while genetic therapies would theoretically benefit any DMD patient, molecular therapies are an example of personalized therapies, as they are expected to work only in those patients who harbor specific mutations, targeted by the molecule of choice.

We will first briefly review the current standards in molecular diagnosis of DMD, and then the main molecular treatment strategies accessible to patients with different identified mutations: exon skipping through antisense oligonucleotides (AONs), and readthrough of premature termination codons through the small molecule ataluren. Recently, the prospect of editing patients\' genomes using the CRISPR-Cas9 technology has opened a new exciting perspective in this field.

Genetic diagnosis of DMD {#S2}
========================

Typically, the diagnosis of DMD may be established based on the clinical picture and the finding of absent dystrophin expression in muscle by immunohistochemistry and/or immunoblot ([@R07]). However, internationally adopted guidelines ([@R08], [@R09]) indicate that an accurate characterization of the causative mutation at the genomic level is of paramount importance in order to provide genetic counseling to the family, establish genotype-phenotype correlations and prognosis, and, as we will show in the next paragraphs, assess eligibility for novel molecular treatments. The first molecular assay to be requested when DMD is suspected should be quantitative, i.e. provide a measure of the copy number of genomic regions corresponding to each of the 79 *DMD* exons. In fact, about 60 to 70% of DMD-causing mutations are large rearrangements (deletions or duplications) including one or more exons ([@R10]). These are readily identified in both affected males and female carriers by multiplex ligation-dependent probe amplification (MLPA) ([@R11]). In the case of single-exon deletions, results should be confirmed by an independent technique, as some small mutations may prevent probe hybridization and be misinterpreted as deletions of the corresponding exons. Alternative quantitative techniques include multiplex PCR and competitive genomic hybridization (CGH) arrays. Whenever quantitative assays cannot completely characterize the mutation, PCR amplification and sequencing of the coding *DMD* regions and flanking nucleotides allows the identification of single nucleotide substitutions, small sub-exonic rearrangements, and canonic splice-site mutations. While classic Sanger sequencing is still widely used, next generation sequencing (NGS) approaches are becoming increasingly accessible ([@R09]). In rare cases in which no mutation can be identified by sequencing of genomic DNA coding regions, *DMD* mRNA may be isolated from skeletal muscle tissue (either archived from a previous diagnostic biopsy, or obtained specifically for this purpose), reversetranscribed to cDNA, and sequenced. The localization of sequence anomalies in the transcript may point to deep intronic causative mutations that may be identified by targeted Sanger sequencing of intronic gDNA regions, or by NGS. The systematic application of this workflow in DMD patients (illustrated in [Fig. 1](#F1){ref-type="fig"}) leads to the identification of a clear pathogenetic mutation in the vast majority of cases.

![Flow diagram of genetic diagnosis in DMD, highlighting indicated molecular assays (blue circles) and corresponding possible findings (red rectangles), leading to further assays, or, in some cases, to established amenability for molecular treatments (green rectangles).](1128-2460-35-122-g001){#F1}

Exon skipping with antisense oligonucleotides {#S3}
=============================================

The rationale for \"exon skipping\" is based on several facts: in about two thirds of cases, DMD is caused by large deletions involving one or more exons, and disrupting the *DMD* open reading frame (ORF); on the contrary, deletions that respect the ORF cause the milder allelic disease BMD ([@R12]); because of the *DMD* genomic structure, it is often possible to restore the ORF of an out-offrame deletion by splicing out just one exon, adjacent to the deletion borders at the 5\' or 3\' side, from the mature mRNA. Therefore, by targeting and inactivating specific exon splicing signals in the pre-mRNA with sequencespecific AONs, it is possible to obtain an internally deleted, yet in-frame *DMD* transcript, which is similar to transcripts naturally observed in BMD patients. These transcripts may then be translated into a viable, albeit internally deleted and quantitatively reduced, dystrophin protein, hopefully shifting the patient\'s clinical picture towards the milder BMD phenotype. The application of AON treatments to DMD and other genetic conditions became technically possible in the early 2000s, with the invention of chemically modified nucleotide backbones, which resisted to nucleases and had a favourable pharmacokinetic and pharmacodynamic profile in humans. These were 2\'-O-methyl RNA phosphorothioate AONs (administered subcutaneously) and morpholino AONs (administered intravenously) ([@R13]). For both chemistries, first-in-human studies with local intramuscular injections of AONs showed promising dystrophin restoration in biopsies of injected muscles ([@R14] ,[@R15]). The leading compounds targeted exon 51, whose skipping is predicted to restore the ORF in the highest portion of DMD patients (around 10-15%). Subsequent phase 2 dose-escalation studies ([@R16], [@R17]) were also promising, as they seemed to provide not only assurances of good tolerability of these compounds, but also biochemical evidence of dystrophin restoration and encouraging stabilization or improvement of some functional outcome measures. Unfortunately, in the years immediately following these exciting breakthroughs, the enthusiasm of the DMD community was thwarted. An international, multi-center phase 3 trial of drisapersen (clinicaltrials.gov NCT01254019), the 2\'-Omethyl AON for the skipping of exon 51 developed by Biomarin/Prosensa, failed to achieve a significant clinical benefit (the results have not yet been published). While more partially encouraging data came from a phase 2b extension study ([@R18]), the company decided to discontinue the drisapersen development program. These events have triggered a lively debate ([@R19], [@R20]) about several controversial aspects of exon skipping treatments, such as the difficulty to accurately measure efficacy of treatments both at the molecular ([@R21]) and clinical level ([@R22]), and the amount of dystrophin needed to actually obtain a clinical benefit ([@R23]). As for eteplirsen, the morpholino AON for the skipping of exon 51 developed by Sarepta, phase 3 studies are still underway (NCT02255552), but interesting data have derived from a small but prolonged phase 2b extension study ([@R24]). Clinical data from this open-label study, also corroborated by comparison to a mutationmatched external natural history control group ([@R25]), seem to support stabilization of ambulatory function in 12 patients. Unfortunately, data regarding dystrophin quantification in several longitudinal muscle biopsies in the same study indicate less abundant protein expression increase than suggested by earlier studies, and have been the object of controversy ([@R26], [@R27]). Despite these uncertainties, the Food and Drugs Administration has recently granted accelerated approval to eteplirsen in the United States of America, recognizing that a demonstrated increase in a biologically relevant biomarker, i.e. dystrophin, however small, may reasonably be expected to benefit DMD patients ([@R06]). Hopefully, successful confirmatory trials will allow the clinical efficacy of exon skipping AONs to be established without ambiguity. Clinical trials of AONs targeting exons other than 51 are underway (e.g. NCT02310906 and NCT02500381), and new generations of AONs are being experimented at the preclinical stage ([@R28], [@R29]), so that exon skipping still represents a promise of future effective treatments for a large portion of DMD patients.

Stop codon readthrough compounds {#S4}
================================

About 15% of the causative mutations in DMD are single nucleotide substitutions introducing a premature termination codon (nonsense mutations) ([@R10]). This causes the ribosomial complex to stall during translation, usually resulting in nonsense-mediated decay of the transcript and absence of dystrophin ([@R30]). However, nonsense mutations may also be observed in association with BMD or intermediate phenotypes, probably due to naturally occuring alternative splicing of in-frame exons ([@R31]). Furthermore, ribosomes may be pharmacologically induced to \"read through\" premature stop codons, and continue downstream translation, giving rise to normal dystrophin. Aminoglycosides were demonstrated to effectively promote dystrophin expression in the *mdx* mouse model, which carries a nonsense mutation in exon 23 ([@R32]), but human trials were hindered by excessive toxicity ([@R33], [@R34]). The pharmaceutical company PTC Therapeutics has developed a small molecule compound, ataluren, which has been shown to maintain the same nonsense readthrough effect as aminoglycosides (although the exact molecular mechanism has not been completely cleared) ([@R35]) with a more favorable tolerability profile. After proof-of-concept studies in animal models ([@R36]) and phase 1 trials showing no relevant safety issues ([@R37]), ataluren was dosed in DMD in a first phase 2a study with further reassurance of safety, and encouraging results ([@R38]). The results of a larger phase 2b trial were controversial ([@R39]), as the primary endpoint (48-week change in the 6 minute walk test \[6MWT\]) was not achieved, and better ambulation outcomes were unexpectedly observed in a 10, 10, 20 mg/kg than 20, 20, 40 mg/kg study arm. Unfortunately, quantitative assessments of dystrophin restoration in muscle tissue from participant biopsies were hindered by technical issues in this study. However, indications of efficacy in the phase 2b study were sufficient for the European Medicines Agency to issue a conditional approval for the marketing of ataluren in European Union countries in 2014 ([@R05]), with the obligation on the company\'s part to conduct a phase 3 confirmatory study, the results of which (NCT01826487) have recently been released online (<http://ir.ptcbio.com/releasedetail.cfm?ReleaseID=936905>) although not yet published as a peer-reviewed article. While the primary endpoint of change in the 6MWT still remained elusive, pre-specified subgroup analyses and meta-analyses in conjunction with the previous phase 2b study showed a clear, although not dramatic drug effect in delaying the deterioration of ambulatory function in DMD. Currently, ataluren is prescribable to DMD patients with nonsense mutations who are older than 5 years and ambulatory in several European countries. The continued development of the nonsense readthrough strategy will hopefully provide a solid therapeutic option for a relevant subgroup of DMD patients.

\"Exon snipping\": mutation-specific gene editing {#S5}
=================================================

Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) systems are an adaptive immune defense evolved in bacteria and archaea, which uses short RNAs for the degradation of foreign nucleic acids. In 2013, several independent groups reported the successful reprogramming of CRISPR-Cas9 to cut DNA at any site of choosing in eukaryotic cells, by coupling it with a strand of guide RNA (gRNA) with a custom sequence ([@R40]-[@R42]). This breakthrough invention has revolutionized molecular biology with its myriad potential applications. Applied to DMD, the CRISPR-Cas9 approach has been aptly named \"exon snipping\" ([@R43]), in analogy with the \"exon skipping\" obtained by AON targeting of mRNA. \"Exon snipping\" would primarily consist in excising an in-frame exon containing a small nonsense or frameshifting mutation, as successfully demonstrated with adeno-associated virus (AAV) delivery in the mdx murine model ([@R44], [@R45]), or, alternatively, in excising specific exons in order to restore the ORF in the case of large rearrangements (deletions or duplications) ([@R46]). The main drawbacks of this approach are represented by the challenges of AAV vector delivery in humans, and the fear of off-target effects. Nevertheless, the versatility and wide applicability of this technology to virtually every DMD causing mutation makes it one of the most exciting and promising novel approaches to molecular therapy of DMD.

Conclusions {#S6}
===========

The advancements of molecular treatments described above have made reaching a precise genetic diagnosis in DMD more and more important over the last few years. Currently, DMD patients with deletions bordering exon 44, 45, 51 or 53 bordering may be eligible for recruitment in one of several ongoing clinical trials of exon skipping. Patients eligible for exon 51 skipping may be treated with commercialized eteplirsen in the United States (Exondys 51^®^, Sarepta Therapeutics, Cambridge, MA, USA). Patients in whom MLPA (or other equivalent quantitative assays for large deletions/duplications) tests negative, should be studied with *DMD* gene sequencing in order to be able to provide genetic counseling to the family, and because patients with nonsense mutations may be eligible for treatment with ataluren, commercialized as Translarna^®^ in the European Union (PTC Therapeutics, South Plainfield, NJ, USA), or within future clinical trials. While the advancement of these treatments has been painstakingly slow in the eyes of DMD patients and their families, who struggle every day against the progression of this disabling disease, there are reasons to hope that the experience gathered in designing better clinical trials, as well as an increasing number of novel drugs in the pipeline of preclinical research, will bring on a faster and more effective translation of scientific findings into benefit for patients in the upcoming years.
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